TY - JOUR
T1 - Development of a multiplex serological assay to detect immunoreactivity against a novel Bartonella species in military working dogs
AU - de Araujo, Fernanda Fortes
AU - Safko, Jennifer
AU - Bolton, Jessica
AU - Jiang, Le
AU - Cooper, Edwin
AU - Jenkins, Sarah
AU - Breitschwerdt, Edward
AU - Aronson, Naomi
AU - Bergmann-Leitner, Elke
PY - 2025/10/7
Y1 - 2025/10/7
N2 - Bartonella pose a significant health risk to military working dogs (MWDs), and these zoonotic organisms may also cause disease in humans. According to the U.S. Army zoonotic disease surveillance program, there was a 47.4% seroprevalence for Bartonella spp. among feral dogs in Iraq. This surveillance program identified infection with a novel species Candidatus Bartonella merieuxii (CBm) in 37% of the dogs by whole blood Bartonella DNA amplification and sequencing for the gltA and rpoB genes and intergenic spacer region. This bacterium has not been successfully cultured to date. The objectives of the present study were to (i) develop an assay to serologically detect infection with CBm in dogs, and (ii) to define the prevalence and Bartonella species acquired by MWD during deployment to Iraq. To establish a multiplex serological surveillance panel capable of assessing infection with Bartonella spp., with special emphasis on CBm, we identified in silico 20 peptides representing potential linear B cell epitopes. The newly developed serosurveillance panel was used to test paired samples (pre- and post-Iraq deployment) from 52 MWD. Conventional Bartonella diagnostic testing (PCR and indirect immunofluorescence assays [IFA]) was also performed. Twenty-seven percent (14/52) of the paired samples had statistically significant antibody differences between pre- and post-Iraq deployment, suggesting seroconversion during deployment. In conclusion, the newly developed multiplex serologic assay, with its advantages of high throughput testing, requirement of low sample volumes, and ability to adapt new Bartonella species to the panel, has the potential to serve as a new diagnostic tool and will be useful for serosurveillance.IMPORTANCEBartonella pose a significant health risk to military working dogs (MWDs), and these organisms also cause disease in humans. Bartonella has not been assessed in MWD deployed to Iraq, despite a report that a novel Bartonella, Candidatus B. merieuxii (CBm), was detected in almost half of the stray dogs in Baghdad. Infection in dogs is similar to that in humans, and to date, at least three MWDs have died of Bartonella infection. The goal of the proposed study is to develop an assay to serologically detect infection with CBm in dogs and to define the prevalence and Bartonella species acquired by MWD during deployment to Iraq. Dogs are potential reservoirs and sentinels for vector-borne infections and are implicated in the transmission of these infections to humans. Detecting the presence of Bartonella in Iraq-deployed MWDs is essential to identify and prevent the introduction of a new Bartonella species to North America.
AB - Bartonella pose a significant health risk to military working dogs (MWDs), and these zoonotic organisms may also cause disease in humans. According to the U.S. Army zoonotic disease surveillance program, there was a 47.4% seroprevalence for Bartonella spp. among feral dogs in Iraq. This surveillance program identified infection with a novel species Candidatus Bartonella merieuxii (CBm) in 37% of the dogs by whole blood Bartonella DNA amplification and sequencing for the gltA and rpoB genes and intergenic spacer region. This bacterium has not been successfully cultured to date. The objectives of the present study were to (i) develop an assay to serologically detect infection with CBm in dogs, and (ii) to define the prevalence and Bartonella species acquired by MWD during deployment to Iraq. To establish a multiplex serological surveillance panel capable of assessing infection with Bartonella spp., with special emphasis on CBm, we identified in silico 20 peptides representing potential linear B cell epitopes. The newly developed serosurveillance panel was used to test paired samples (pre- and post-Iraq deployment) from 52 MWD. Conventional Bartonella diagnostic testing (PCR and indirect immunofluorescence assays [IFA]) was also performed. Twenty-seven percent (14/52) of the paired samples had statistically significant antibody differences between pre- and post-Iraq deployment, suggesting seroconversion during deployment. In conclusion, the newly developed multiplex serologic assay, with its advantages of high throughput testing, requirement of low sample volumes, and ability to adapt new Bartonella species to the panel, has the potential to serve as a new diagnostic tool and will be useful for serosurveillance.IMPORTANCEBartonella pose a significant health risk to military working dogs (MWDs), and these organisms also cause disease in humans. Bartonella has not been assessed in MWD deployed to Iraq, despite a report that a novel Bartonella, Candidatus B. merieuxii (CBm), was detected in almost half of the stray dogs in Baghdad. Infection in dogs is similar to that in humans, and to date, at least three MWDs have died of Bartonella infection. The goal of the proposed study is to develop an assay to serologically detect infection with CBm in dogs and to define the prevalence and Bartonella species acquired by MWD during deployment to Iraq. Dogs are potential reservoirs and sentinels for vector-borne infections and are implicated in the transmission of these infections to humans. Detecting the presence of Bartonella in Iraq-deployed MWDs is essential to identify and prevent the introduction of a new Bartonella species to North America.
KW - Bartonella
KW - electro-chemiluminescence
KW - exposure
KW - Iraq
KW - multiplex testing
KW - serology
UR - http://www.scopus.com/inward/record.url?scp=105017990279&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/ea9921ba-53df-3513-a75f-4762f81fba86/
U2 - 10.1128/spectrum.00714-25
DO - 10.1128/spectrum.00714-25
M3 - Article
C2 - 40910773
AN - SCOPUS:105017990279
SN - 2165-0497
VL - 13
SP - e0071425
JO - Microbiology Spectrum
JF - Microbiology Spectrum
IS - 10
ER -